Kuros Biosciences AG - Company Profile
Powered by 
All the data and insights you need on Kuros Biosciences AG in one report.
$295
- Save hours of research time and resources with
our up-to-date Kuros Biosciences AG Strategy Report
- Understand Kuros Biosciences AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Kuros Biosciences AG (Kuros Biosciences) develops products for tissue repair and regeneration. The company develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It focuses on bone repair for trauma, fracture repair and spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair and surgical sealants. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure-resistant, rapid closure of the damaged tissues. The company operates in Schlieren, Switzerland; Bilthoven, the Netherlands; Burlington, USA and in Konstanz, Germany. Kuros Biosciences is headquartered in Schlieren, Zurich, Switzerland.
Headquarters
Switzerland
Address
Wagistrasse 25, Schlieren, Zurich, 8952
Website
kurosbio.com
Telephone
41 44 7334747
No of Employees
80
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KURN (SWF)
Revenue (2022)
$37.4M
86.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
5.9%
(2022 vs 2021)
Market Cap*
$271.2M
Net Profit Margin (2022)
XYZ
49.6%
(2022 vs 2021)
* As of and is in US$
Kuros Biosciences AG premium industry data and analytics
Products and Services
| Products |
|---|
| Commercialized |
| MagnetOs product family: |
| MagnetOs Putty - Spinal (Posterior Lumbar Fusion), Orthopedics, Dental |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Kuros Biosciences AG | F. Hoffmann-La Roche Ltd | Novartis AG | Allergan Ltd. | Aristo Pharma GmbH |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | Switzerland | United Kingdom | Germany |
| City | Schlieren | Basel | Basel | Marlow | Berlin |
| State/Province | Zurich | - | - | England | Berlin |
| No. of Employees | 80 | 103,605 | 76,057 | - | 1,218 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Clemens van Blitterswijk | Chairman; Director | Executive Board | 2018 | 67 |
| Joost de Bruijn, Ph.D. | Director; Chief Executive Officer | Executive Board | 2018 | 58 |
| Philippe Saudan, Ph.D. | Chief Development Officer | Executive Board | 2016 | 53 |
| Chris Fair | Chief Operating Officer | Senior Management | 2022 | - |
| Daniel Geiger | Chief Financial Officer - Interim | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer